May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Comparison of Ocular Side Effects Between 0.3% Gatifloxacin and 0.5% Moxifloxacin
Author Affiliations & Notes
  • A. Avakian
    University of Sao Paulo, Sao Paulo, Brazil
    Cataract,
  • P. H. Menezes
    University of Sao Paulo, Sao Paulo, Brazil
    Ophthalmology,
  • D. L. Peixoto
    University of Sao Paulo, Sao Paulo, Brazil
    Ophthalmogy,
  • W. T. Hida
    University of Sao Paulo, Sao Paulo, Brazil
    Ophthalmology,
  • G. M. S. Andrade
    University of Sao Paulo, Sao Paulo, Brazil
    Ophthalmology,
  • A. Avakian
    University of Sao Paulo, Sao Paulo, Brazil
    Ophthamology,
  • Footnotes
    Commercial Relationships  A. Avakian, None; P.H. Menezes, None; D.L. Peixoto, None; W.T. Hida, None; G.M.S. Andrade, None; A. Avakian, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 1990. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Avakian, P. H. Menezes, D. L. Peixoto, W. T. Hida, G. M. S. Andrade, A. Avakian; Comparison of Ocular Side Effects Between 0.3% Gatifloxacin and 0.5% Moxifloxacin. Invest. Ophthalmol. Vis. Sci. 2008;49(13):1990. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To analyze and compare pupil size, conjunctival hyperemia, ocular irritation and pain in individuals undergoing cataract preoperative prophylactic therapy with 0.3% Gatifloxacin and 0.5% moxifloxacin ophthalmic solution.

Methods: : This prospective randomized comparative study included 60 eyes of 60 patients undergoing cataract preoperative prophylactic therapy . Patients scheduled for routine phacoemulsification were given, in a double masked fashion, either moxifloxacin 0.5% (VigamoxTM) (n=30) or gatifloxacin 0.3% (ZymarTM) (n=30) one drop every 15 minute (5 times) before the surgical procedure. Ocular side effects (pupil size, conjunctival hyperemia, ocular irritation, and pain) was scored according to a numerical scale of 1 to 5 in both groups. Pupil size was measured by a pupilometer and conjunctival hyperemia was scored by one clinician only. Ocular irritation and pain was scored by the patient. Five minutes after the last application, patients were submitted to slit lamp examination under standard room and luminance condition and graded according to numerical scale. Statistical analysis was performed using analysis of variance (ANOVA).

Results: : Pupil size in moxifloxacin group was significantly smaller when compared to gatifloxacin group (p<0,05). Conjunctival hyperemia scored by the clinician did not show any statistical difference. Ocular irritation and pain scored by the patient also did not show any statistical difference.

Conclusions: : There are no difference in side effects (conjunctival hyperemia, ocular irritation and pain) in individuals undergoing cataract preoperative prophylactic therapy with 0.3% gatifloxacin and 0.5% moxifloxacin ophthalmic solution. However, the effect of 0.3% gatifloxacin in the pupil size can have a benefic influence in the surgical outcome.

Keywords: antibiotics/antifungals/antiparasitics • drug toxicity/drug effects • inflammation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×